Management

Dr. Martell is Chief Scientific Officer at Curis, having previously served as Head of Research and Development. He is also currently Attending Physician in the Division of Hematology/Oncology at the University of Vermont Medical Center. Prior to joining the Curis in 2018, he served on Curis’s Board of Directors. Prior to Curis, he was Chief Medical Officer of Tesaro and MethylGene and held previous leadership positions at Bristol-Myers Squibb and Bayer. In addition, Dr. Martell is co-founder of Epi-Cure Pharmaceuticals, and serves on the Board of Directors of Indaptus Therapeutics. Throughout most his Career, he has maintained significant research and/or patient care activities at academic institutions, including Tufts Medical Center, Yale Health Center, Duke University Medical Center and in Veteran’s Affairs Medical Centers. Dr. Martell received a B.A. in chemistry from Kalamazoo College, a Ph.D. in Pharmacology from University of Michigan, and an M.D. from Wayne State University, and subsequently completed his Internal Medicine Residency and Medical Oncology Fellowship training at Duke.